NCRI’s Cellular Molecular Pathology Initiative share new priorities
NCRI’s Cellular Molecular Pathology Initiative (CM-Path) aim to change the way pathologists engage with, conduct and are recognised for their work in clinical trials in the UK. You can find out more about CM-Path’s priorities on the website.